Abiopharma

🔍 Dambkowski Carl (Executive)

Company: Apogee Therapeutics, Inc. (APGE)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 14,025 shares of Common Stock at $22.86 per share (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 231,223.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,954 shares of Common Stock at $77.13 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 228,269.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 14,820 shares of Common Stock at $77.9 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 213,449.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 826 shares of Common Stock at $79.04 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 212,623.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 100 shares of Common Stock at $80.06 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 212,523.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 14,025 shares of Stock Option (Right to Buy) at $22.86 per share (Derivative)
  Date: 2026-01-07 | Code: M | Expires: 2033-12-18 | equity_swap_involved: 0 | shares_owned_after: 139,540.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Due to an administrative error, the amount reported in Column 5 on the reporting person's Form 4 filed on October 3, 2025 was overstated by 53,910 shares. As a result, the beneficial ownership totals reported in the reporting person's Forms 4 filed after October 3, 2025 were each overstated by 53,910 shares. This Form 4 reflects the correct amount of common stock beneficially owned by the reporting person.
• F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.44 to $77.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.45 to $78.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.70 to $79.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F6: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.